April 25, 2019
Sensient Declares Dividend
The Board of Directors of Sensient Technologies Corporation has declared a regular quarterly cash dividend on its common stock of$0.36 per share.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
April 25, 2019
Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The safety profile of KEYTRUDA was consistent with thatpreviously observed in gastric cancer
April 25, 2019
Teva Pharmaceuticals USA, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply
Teva recalls 35 lots of bulk LosartanPotassium USP Tablets.
April 25, 2019
Celgene Reports First Quarter 2019 Operating and Financial Results
Celgene posts strong double-digit top- and bottom-line growth across portfolioand geographies
April 25, 2019
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m.…
April 25, 2019
Seattle Genetics Reports First Quarter 2019 Financial Results
-ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada Were $135.0 Million in the First Quarter, an Increase of 42…
April 25, 2019
Drug Addiction Pipeline Review, H1 2019 – Therapeutic Analysis of 28 Companies & Drug Profiles – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Drug Addiction – Pipeline Review, H1 2019” report has been added to ResearchAndMarkets.com’s offering. Drug Addiction – Pipeline…
April 25, 2019
Multiple Myeloma Epidemiology Forecast to 2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Multiple Myeloma: Epidemiology Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. In 2017, the 8MM had…
April 25, 2019
Global Idiopathic Pulmonary Fibrosis Competitive Landscape to 2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Idiopathic Pulmonary Fibrosis: Competitive Landscape to 2026” report has been added to ResearchAndMarkets.com’s offering. “Idiopathic Pulmonary Fibrosis: Competitive…
April 25, 2019
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating…